^
    Back
    Association details:
    Biomarker:CD74-NRG1 fusion + EGFR mutation + HER-2 mutation
    Cancer:Lung Adenocarcinoma
    Drug:Gilotrif (afatinib) (pan-HER inhibitor) +
    Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Thorac Cancer
    Title:

    A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy

    Published date:
    09/12/2022
    Excerpt:
    ...we report a multiple primary lung adenocarcinoma patient harboring the CD74-NRG1 fusion, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (ERBB2) mutation simultaneously. The patient received afatinib and pyrotinib combination therapy and showed a significant treatment response with a progression-free survival of 5 months.
    DOI:
    https://doi.org/10.1111/1759-7714.14636